Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...

Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in ...

Labcorp LH recently announced that the Labcorp Plasma Detect was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research. Labcorp Plasma Detect is a ...

Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 ...

Quest Diagnostics has received approval from the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Programme for its Haystack minimal residual disease (MRD) test, expanding ...

SEATTLE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...